Cortistatin: Physiology and What Research Reports

What cortistatin is

Cortistatin is a small neuropeptide that shares structural similarity with somatostatin, and the two peptides are frequently studied together as a single signalling system; research assessing the diagnostic, prognostic and therapeutic potential of the somatostatin/cortistatin system in glioblastoma reflects that combined framing (PMID 40268793). A 2019 review characterised cortistatin as a novel cardiovascular protective peptide and summarised its expression and signalling in cardiovascular tissue (PMID 31555545). Because of that overlap, readers who encounter the term in peptide literature usually meet it alongside somatostatin receptor biology rather than on its own.

Where it is produced and what it appears to do

Cortistatin was originally identified in cortical neurons, and subsequent work has examined its expression in immune, vascular and cardiac tissue; the review of cortistatin as a cardiovascular peptide described roles in vascular and cardiac tissue in that context (PMID 31555545). Unlike somatostatin, cortistatin has been reported to interact with additional targets: one study reported that cortistatin binds to TNF-α receptors and protected against osteoarthritis in an experimental model (PMID 30826358). That combination of somatostatin-receptor and inflammation-related interactions is the main reason cortistatin is discussed as an immunomodulatory peptide rather than purely a neuroendocrine one.

How cortistatin is measured and studied

Two broad approaches appear in the literature. The first measures endogenous cortistatin in human serum as a candidate biomarker. Researchers reported decreased maternal serum cortistatin levels in pregnancies affected by gestational diabetes mellitus compared with controls (PMID 31154879), and a separate study measured serum cortistatin levels in patients with ocular active and ocular inactive Behçet disease (PMID 31314641). The second approach administers cortistatin, or an engineered version of it, to animals and cell systems; a study of a latent form of cortistatin evaluated therapeutic effects in experimental inflammatory and fibrotic disorders, an example of peptide engineering aimed at stability and targeting (PMID 36559278).

Tissue and receptor-level studies

In tumour biology, the somatostatin/cortistatin system has been profiled in glioblastoma samples and models to ask whether components of the system carry diagnostic or prognostic information and whether they represent therapeutic targets (PMID 40268793). In skin biology, a 2026 study reported that cortistatin antagonised the Piezo1–STING axis and supported mitochondrial homeostasis in keratinocytes by attenuating advanced glycation end-product accumulation in diabetic ulcers (PMID 41826727).

What the literature reports

The published evidence base is dominated by animal and cell models. The table below summarises the reported direction of findings in the cited papers; each entry links to the source, and none of these findings has been extended to approved human therapy.

Neurological and neuroimmune work

The stroke study is a useful example of how cortistatin is framed in neuroscience: researchers reported both immunomodulatory and neuroprotective components in a preclinical model of ischaemic stroke, rather than a single mechanism (PMID 39521024). A 2024 paper made a similar multi-target argument for Parkinson's disease, describing cortistatin as a candidate multimodal therapy (PMID 38255772).

Cardiovascular and metabolic work

Cardiovascular findings include reduced atherosclerosis in hyperlipidaemic ApoE-deficient mice together with reduced foam cell formation (PMID 28406244) and cardioprotection against isoproterenol-induced myocardial injury in rats (PMID 32355753). On the metabolic side, the observational finding of lower maternal serum cortistatin in gestational diabetes mellitus is an association measured in pregnancy, not evidence that changing cortistatin levels alters outcomes (PMID 31154879).

Safety and Adverse Events: What Studies Report

The cited literature does not provide a human safety dataset for administered cortistatin. In the ischaemic stroke work, the reported outcomes were immunomodulatory and neuroprotective effects in a preclinical model, not a characterised adverse-event profile (PMID 39521024). Where engineered formats were tested, such as the latent cortistatin construct evaluated in experimental inflammatory and fibrotic disorders, the reported outcomes were therapeutic effects in animal models (PMID 36559278), and the osteoarthritis study likewise reported receptor binding and protection in an experimental setting rather than human tolerability data (PMID 30826358). Human measurements in the cited papers were observational serum levels in Behçet disease (PMID 31314641) and in gestational diabetes (PMID 31154879), which report no exposure and therefore no safety signal. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment decision.

Why the term matters in peptide research

Cortistatin appears in peptide discussions for three reasons. First, it sits inside a well-mapped receptor family, which makes it attractive for target-based work such as the glioblastoma system profiling (PMID 40268793). Second, it has been reported to act on inflammation-related targets beyond somatostatin receptors (PMID 30826358). Third, short native peptides are typically short-lived, so engineering approaches such as the latent format were developed and tested in disease models (PMID 36559278).

Limitations of the current evidence

• Most reported effects come from rodent or cell models, including uveitis (PMID 32823415) and myocardial injury studies (PMID 32355753).
• Human data in the cited set are cross-sectional biomarker measurements rather than interventional trials (PMID 31314641).
• Mechanistic findings such as Piezo1–STING antagonism are model-specific and await independent replication (PMID 41826727).

Cortistatin is a research peptide, not an approved medicine, and nothing on this page describes an administration protocol.

References

• Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke (Pharmacological Research, 2024)
• Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma (Cellular and Molecular Life Sciences, 2025)
• Cortistatin antagonizes Piezo1-STING axis and facilitates mitochondrial homeostasis of keratinocytes by attenuating AGEs accumulation in diabetic ulcers (Cell Death and Differentiation, 2026)
• Cortistatin binds to TNF-α receptors and protects against osteoarthritis (EBioMedicine, 2019)
• Decreased maternal serum cortistatin levels in pregnancies with gestational diabetes mellitus (Journal of Maternal-Fetal & Neonatal Medicine, 2020)
• Cortistatin, a novel cardiovascular protective peptide (Cardiovascular Diagnosis and Therapy, 2019)
• Therapeutic Effect of a Latent Form of Cortistatin in Experimental Inflammatory and Fibrotic Disorders (Pharmaceutics, 2022)
• Serum Cortistatin Levels in Patients with Ocular Active and Ocular Inactive Behçet Disease (Ocular Immunology and Inflammation, 2020)
• Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease (International Journal of Molecular Sciences, 2024)
• Anti-inflammatory effect of cortistatin in rat endotoxin-induced uveitis model (Indian Journal of Ophthalmology, 2020)
• Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats (Annals of Translational Medicine, 2020)
• Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells (Scientific Reports, 2017)